Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ian Massey Insider Profile
4 Followers
Ian Massey, CEO at Microbot Medical, holds 2.02M shares in Microbot Medical (Ticker: MBOT), holds 23.44K shares in Novelion Therapeutics (Ticker: NVLNF).
Ian Massey has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
CEO
Roles that Ian Massey holds in companies
Most Profitable Insider Trade
Stock:
Novelion Therapeutics
(NVLNF)
(NVLNF)
Rating:Informative Buy
Date:May 15, 2009 - May 15, 2010
Return:+190.20%
The most profitable trade made by Ian Massey
Ian Massey's Trading History
Microbot Medical
Apr 18, 2016
CEO
Uninformative Buy
―
$2.12M
Novelion Therapeutics
May 15, 2009
―
Informative Buy
30.07K
$16.45K
List of latest transactions for each holding click on a transaction to see Ian Massey's performance on stock
You May Also Like
Ian Massey insider profile FAQ
What is the percentage of profitable transactions made by Ian Massey?
The percentage of profitable transactions made by Ian Massey is ―.
What is the average return per transaction made by Ian Massey?
The average return per transaction made by Ian Massey is ―.
What stocks does Ian Massey hold?
Ian Massey holds: MBOT, NVLNF stocks.
What was Ian Massey’s latest transaction?
Ian Massey latest transaction was an Uninformative Buy of ―.
What was Ian Massey's most profitable transaction?
Ian Massey’s most profitable transaction was an Informative Buy of NVLNF stock on May 15, 2009. The return on the trade was 190.20%.
What is Ian Massey's role in Microbot Medical?
Ian Massey's role in Microbot Medical is CEO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.